Triple punch against pancreatic cancer: chemo, immunotherapy, and radiation before surgery

NCT ID NCT06384560

Recruiting now Disease control Sponsor: Amsterdam UMC, location VUmc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new approach for people with pancreatic cancer that can be surgically removed. Before surgery, patients receive a combination of chemotherapy (mFOLFIRINOX), an immunotherapy drug (pembrolizumab), and targeted radiation (SABR). After surgery, they continue with chemotherapy and immunotherapy. The goal is to see if this triple treatment helps patients live longer without the cancer coming back. The trial is for adults with early-stage or borderline resectable pancreatic cancer who are healthy enough to undergo these treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA LOCALIZED PANCREATIC ADENOCARCINOMA RESECTABLE PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

Amsterdam University Medical Center
RECRUITING

Amsterdam, Netherlands
Erasmus University Medical Center
RECRUITING

Rotterdam, Netherlands
Maastricht University Medical Center
NOT_YET_RECRUITING

Maastricht, Netherlands
St. Antonius Ziekenhuis
RECRUITING

Nieuwegein, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.